Shali Biotech

Shali Biotech — 北京沙砾生物医药股份有限公司 — appears in elsewhere's corpus almost entirely through its spin-out: in June 2025, its in vivo CAR-T platform was split off to form Weitao Biotech (微滔生物), a Shanghai-based company developing targeted LNP-delivered in vivo CAR-T therapies for hematologic cancers and autoimmune diseases. That spin-out quickly raised an angel round of over RMB 100 million led by Qiming Venture Partners, followed by A and A+ rounds totaling over $50 million, with Qiming continuing to back it; its lead asset GT801 presented initial human data orally at ASH 2025 . Notably, Qiming partner Chen Kan cited "Shali Biotech's FTE model" as a safeguard for the spin-out's R&D efficiency, suggesting the parent retained a service relationship with Weitao . Beyond this, elsewhere's corpus does not cover Shali Biotech's own founding, pipeline, or financing in any detail.